[Dimethyl fumarate (tecfidera) is the first line treatment choice in patients with remitting multiple sclerosis].

Authors
Category Primary study
JournalZhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Year 2017
Dimethyl fumarate (DMF) is a new oral option for disease-modifying therapy (DMT) in patients with remitting multiple sclerosis as a first line treatment. The results of international randomized studies comparing DMF with placebo and other DMTs are presented. DMF is a DMT with promised efficacy and favorable safety profile that could be a treatment option for patients with suboptimal response for other first line DMTs and used as initial therapy for treatment-naive patients with unfavorable prognostic factors.
Epistemonikos ID: d895a2da441f9382a14222e31b931e3006efd944
First added on: Nov 05, 2021